CLINICAL TRIALS PROFILE FOR VASOTEC

All Clinical Trials for VASOTEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	US Department of Veterans Affairs	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	VA Office of Research and Development	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00741156 ↗	The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution	Completed	The Hospital for Sick Children	Phase 3	2008-07-01	The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT00895414 ↗	Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer	Completed	Masonic Cancer Center, University of Minnesota	N/A	2009-04-01	RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
NCT01413542 ↗	Pharmacogenetics of Ace Inhibitor-Associated Angioedema	Completed	Vanderbilt University	N/A	2011-11-01	The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

Clinical Trial Conditions for VASOTEC

Condition Name

Condition Name for VASOTEC
Intervention	Trials
Hypertension	3
Hypertension, Resistant to Conventional Therapy	1
Hypotension on Induction	1
Metastatic Malignant Melanoma	1

Condition MeSH

Condition MeSH for VASOTEC
Intervention	Trials
Hypertension	3
Hypotension	2
Wounds and Injuries	1
Diabetes Mellitus, Type 2	1

Clinical Trial Locations for VASOTEC

Trials by Country

Trials by Country for VASOTEC
Location	Trials
United States	5
Canada	1
Norway	1

Trials by US State

Trials by US State for VASOTEC
Location	Trials
Georgia	1
Nebraska	1
Tennessee	1
Minnesota	1
New York	1

Clinical Trial Progress for VASOTEC

Clinical Trial Phase

Clinical Trial Phase for VASOTEC
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VASOTEC
Clinical Trial Phase	Trials
Completed	5
Unknown status	1
Withdrawn	1

Clinical Trial Sponsors for VASOTEC

Sponsor Name

Sponsor Name for VASOTEC
Sponsor	Trials
Brigham and Women's Hospital	2
University of Nebraska	1
Norwegian Cancer Society	1

Sponsor Type

Sponsor Type for VASOTEC
Sponsor	Trials
Other	11
U.S. Fed	2
Industry	1

Vasotec (enalapril): Clinical Trials Update, Market Analysis, and Projection

Last updated: May 4, 2026

What is Vasotec and what is its current clinical footprint?

Vasotec is the brand name for enalapril, an oral ACE inhibitor indicated for hypertension and congestive heart failure (CHF). The product line includes Vasotec tablets and Vasotec Injection for selected clinical settings.

Therapeutic maturity: Vasotec’s active ingredient (enalapril) is well beyond initial launch and is now a mature, off-patent standard-of-care ACE inhibitor in most markets. As a result, the public clinical-trials pipeline is dominated by:

• observational studies, registries, and comparative effectiveness research using enalapril as a comparator
• new labeling/biomarker substudies rather than first-in-class development
• formulation, dosing, and comparative pharmacology studies rather than pivotal new-efficacy programs

Implication for “clinical trials update”: A practical clinical update for Vasotec is typically limited to label-relevant studies and postmarketing evidence rather than new Phase 3 programs.

Which active or recruiting clinical trials exist for enalapril/Vasotec?

No complete, up-to-date trial-by-trial listing can be produced here because the request requires current registry data (e.g., ClinicalTrials.gov status, sponsor, phase, endpoints, and timelines) and the necessary live data source is not provided in the prompt.

What does the market look like for enalapril (Vasotec) by geography and channel?

Because Vasotec is off-patent in most major markets, the economic reality is driven by:

• generic enalapril penetration
• price erosion from multi-source supply
• payer reimbursement dynamics
• distribution channel breadth in ambulatory care

Competitive structure

• Primary competitors: other generic ACE inhibitors (e.g., lisinopril, captopril, ramipril) and branded cardiovascular agents where relevant
• Direct substitutes: generic enalapril products and fixed-dose combinations where used by patients

Key demand drivers

• prevalence of hypertension and CHF
• chronic adherence patterns (ACE inhibitors remain long-term therapy)
• guideline placement of ACE inhibitors in CHF and hypertension management

Channel reality

• Low-cost chronic cardiometabolic therapy is predominantly primary care and cardiology driven
• Hospital use of ACE inhibitors exists but is also heavily genericized, compressing pricing

How should an investor model Vasotec/enalapril sales when it is off-patent?

For off-patent ACE inhibitors, forecasting is usually less about blockbuster-style growth and more about share, price erosion, and formulary persistence.

A workable projection framework uses these components:

1. Underlying treated population (hypertension and CHF cohorts)
2. Utilization rate (ACE inhibitor share within those cohorts)
3. Price erosion (generic competition and periodic downward pricing)
4. Share retention (brand vs generic mix; or, if you are modeling a branded manufacturer, the share of branded remaining demand)
5. Switching dynamics (patients and prescribers can shift across ACE inhibitors and to ARBs or ARNI depending on tolerability)

What is the projection for Vasotec’s market performance?

A quantified market projection requires:

• an explicit market definition (e.g., US prescriptions, EU defined daily doses, global spend)
• baseline sales, units, and time series
• current branded vs generic split
• country coverage and forecast horizon

Those inputs are not present in the prompt, so a complete numeric forecast cannot be generated without fabricating assumptions.

How do clinical evidence and guideline positioning affect enalapril demand?

Even when development is not active, clinical positioning continues to influence steady demand:

• ACE inhibitors remain foundational in CHF management and common in hypertension therapy
• evidence base supports outcome benefit class-wide, not unique to enalapril alone
• safety and tolerability factors (renal function monitoring, hyperkalemia risk, cough, angioedema vigilance) drive prescribing but do not eliminate use

What should be monitored next for Vasotec as a business?

With an off-patent ACE inhibitor, risk and opportunity monitoring is typically focused on:

• generic supply changes and price competition in each major market
• formulary status shifts for competitor ACE inhibitors and ARBs/ARNI classes
• regulatory and manufacturing updates that affect availability and tender outcomes
• utilization shifts for CHF phenotypes and guideline updates that affect ACE inhibitor vs ARB vs ARNI selection

Key Takeaways

• Vasotec (enalapril) is a mature, off-patent ACE inhibitor where public “clinical trial updates” are usually limited to postmarketing, observational, and comparator studies rather than new pivotal efficacy programs.
• Demand is primarily driven by chronic management of hypertension and CHF, while revenue is shaped by generic penetration and price erosion rather than innovation-led growth.
• A quantified clinical-trials inventory and a numerical market projection cannot be completed from the provided prompt because it lacks live registry data and baseline market figures.

FAQs

1) Is Vasotec still undergoing Phase 3 trials?

Not typically. For an off-patent ACE inhibitor like enalapril, public development is usually smaller studies rather than new Phase 3 pivotal programs.

2) What is Vasotec used for today?

It is used for hypertension and congestive heart failure, consistent with ACE inhibitor indications.

3) What most affects enalapril sales?

Generic pricing and formulary positioning, plus treated-population size and utilization in hypertension and CHF.

4) How does competition impact Vasotec?

Multi-source generics compress price; competitors include other ACE inhibitors and therapy alternatives within cardiovascular care.

5) What is the best way to forecast off-patent enalapril?

Model treated population and utilization share, then apply price erosion and expected share retention by channel and country.

---

References

[1] DailyMed. “VASOTEC (enalapril maleate) tablet and injection label.” U.S. National Library of Medicine.
[2] ClinicalTrials.gov. “Enalapril” and “enalapril maleate” search results. U.S. National Library of Medicine.
[3] FDA. “Drug Approval Reports” and related enalapril approval documentation. U.S. Food and Drug Administration.